Shanghai, China – The 2022 Urology & Andrology (UA) Surgery Week & 16^th Forum of Prostate Disease & SIU Training Course, a domestically grand event in urology, kicked off in Shanghai on September 18, 2022. Prominent academicians, experts and scholars in the field of urology research and treatment from all over the country gathered together to present a splendid high-level academic event by combining theory with practice and integrating tradition with innovation online and offline, bringing more than 390 surgical demonstrations and online reviews by top experts. As a leading medical robotics company in China, Shanghai MicroPort MedBot (Group) Co., Ltd. (hereinafter referred to as MicroPort^® MedBot^®) made its debut at the conference, bringing its practical results and latest progress of surgical robotics in urology.

It is known that this academic event is led by the Second Affiliated Hospital of the Naval Medical University, and co-organized by the First Affiliated Hospital of the Naval Medical University, the Third Affiliated Hospital of the Naval Medical University, the Eastern Hospital Affiliated to Tongji University, the Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, and the Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. The five-day Urology Surgery Week, with the theme of “New Technology, New Concept, New Achievement”, adhered to the purpose of “transmitting new concept, sharing new achievement, and making new technology breakthroughs”, and highlighted the characteristics of the military hospital of “military-civilian integration and serving the troops to ensure victories”. Based on the surgery and disease types, it was divided into the Prostate Tumor Disease Day, the Kidney Disease Day, the Bladder Disease Day, the Calculus & Prostate Hyperplasia Disease Day, and the Functional Urology Disease Day, covering almost all urological diseases and surgical methods, thereby popularizing new urological technologies and boosting its growth.

Since it was first held in 2003, the Prostate Disease Forum has always upheld the concept of transmitting and sharing new advances and breakthroughs in scientific and clinical research in the field of prostate disease, learning and growing together with colleagues across the country. After nineteen years of unremitting endeavor, the "Prostate Disease Forum" has developed into a brand meeting in prostate diseases in China.

Since it was first introduced in 2016, the “Surgery Week” has gained the attention and popularity of urologists nationwide with the purpose of boosting academic and business exchanges among urologists and building a platform for the cultivation of young urologists. After six years of unremitting endeavor, the “Surgery Week” has grown into a high-level academic conference with the most comprehensive and numerous live surgical demonstrations in the history of urology conferences in China and even the world at large. It serves as a “major stage” for urology professionals to conduct exchanges, a “wind vane” for the academic frontier of urology, and more importantly, a “training base” for young urologists, playing a significant role in updating the concept of urological disease treatment and enhancing the standardization of surgical techniques.

At the conference, MicroPort^® MedBot^® brought a dazzling array of remarkable achievements and progress in urology to multiple experts in the field. The Toumai^® Laparoscopic Surgical Robot was approved by the National Medical Products Administration in January 2022 and is the first and only Chinese-developed laparoscopic robot that has obtained the registration certificate of urinary surgery general practice so far. Toumai^® has continuously risen to the challenge of complicated surgeries and completed many difficult urological surgeries, assisting clinical experts to achieve numerous landmark breakthroughs with important clinical value, including the first Chinese-developed robotic radical prostatectomy, the first Chinese-developed robotic partial nephrectomy, and the first Chinese-developed robotic partial nephrectomy completed through retroperitoneal approach, marking that China’s independently developed laparoscopic robot can assist doctors in performing complex surgeries in narrow anatomical space, filling the gap of Chinese-developed intellectual manufacturing in this field.

In June 2022, the Toumai^® Laparoscopic Surgical Robot successfully completed a number of urology ultra-long-distance surgeries across a distance of nearly 5,000 km from Kizilsu Kirghiz Autonomous Prefecture, Xinjiang to Nanjing, Jiangsu, realizing the world's longest distance 5G-based remote robotic surgery to date, greatly helping to solve the surgical technology bottlenecks in more hospitals in remote and less developed areas and enhancing the feasibility of the implementation of highly difficult and complex surgeries.

Looking into the future, MicroPort^® MedBot^® will continue to uphold its original aspiration to “Make Surgery Easier, Safer and Less Invasive” to pursue constant technological innovation and application of Chinese-developed surgical robots in urological disease diagnosis and treatment, providing patients with more accurate, safer, and more inclusive consultation service experience and intelligent surgical solutions.